Market capitalization | $3.31m |
Enterprise Value | $-3.92m |
EV/FCF (TTM) EV/FCF | 0.35 |
P/B ratio (TTM) P/B ratio | 0.57 |
Free Cash Flow (TTM) Free Cash Flow | $-11.35m |
Cash position | $7.23m |
P/E forward | negative |
Short interest | 4.78% |
As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.
2 Analysts have issued a Palisade Bio Inc forecast:
2 Analysts have issued a Palisade Bio Inc forecast:
Dec '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -15 -15 |
16%
16%
|
EBIT (Operating Income) EBIT | -15 -15 |
16%
16%
|
Net Profit | -14 -14 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.
Head office | United States |
CEO | J. Finley |
Employees | 8 |
Founded | 2011 |
Website | palisadebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.